

Vinblastine
Essential medicine status
General description

INN
Vinblastine
ATC codes

[L01CA01](#)
Medicine type
Chemical agent

EML status history

First added in 1984 ([TRS 722](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2015 ([TRS 994](#)) for [Hodgkin lymphoma](#)

Added in 2015 ([TRS 994](#)) for [Kaposi sarcoma of unspecified primary site](#)

Added in 2015 ([TRS 994](#)) for [Germ cell tumour of testis](#)

Added in 2015 ([TRS 994](#)) for [Other specified malignant neoplasms of the ovary](#)

Removed in 2015 ([TRS 994](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2021 ([TRS 1035](#)) for [Other specified gliomas of brain](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-positive](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-negative](#)

Added in 2023 ([TRS 1049](#)) for [Langerhans cell histiocytosis](#)

Wikipedia

[Vinblastine](#)

DrugBank

[Vinblastine](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Indications

[Hodgkin lymphoma](#) [Kaposi sarcoma of unspecified primary site](#) [Germ cell tumour of testis](#) [Other specified malignant neoplasms of the ovary](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Langerhans cell histiocytosis](#)